Hatch and Brady Seek to Rewrite Alexander-Murray by Tying CSR Funding to Mandate Delays and HSA Expansion

Congressional Republicans offered insurers one thing they have been demanding for 2018 stability: funding for ACA cost-sharing reduction payments. They paired it with a set of conditions that would reopen the broader health law fight.

According to a Health Affairs update published October 24, Senator Orrin Hatch of Utah and Representative Kevin Brady of Texas proposed changes to the bipartisan Alexander-Murray package that would fund CSR payments through 2019. In exchange, they want Congress to suspend the individual mandate penalty from 2017 through 2019, suspend the employer mandate retroactively from 2015 through 2017, expand the maximum health savings account contribution limit, and add abortion restrictions.

For physicians and practice leaders, this is less about Capitol Hill choreography than what happens to coverage and plan participation in the next two years. CSR payments sit in the plumbing of the individual market. When that funding is unstable, insurers reassess whether to stay in, premiums can shift, and patients show up confused about what they owe and whether they can keep a plan.

What the proposal actually does

The October 24 update centers on a specific trade. Hatch, who chaired the Senate Finance Committee, and Brady, who chaired the House Ways and Means Committee, said they would support funding ACA cost-sharing reduction payments through 2019 if Congress also adopted several changes outside the narrow stabilization framework negotiated by Senators Lamar Alexander and Patty Murray.

Those requested changes are:

• suspend the individual mandate penalty from 2017 to 2019
• suspend the employer mandate retroactively from 2015 to 2017
• expand the HSA maximum contribution limit
• impose additional abortion restrictions

The proposal also takes aim at how insurers would be paid in 2018. Hatch and Brady said insurers receiving CSR payments for 2018 should face conditions to make sure they do not "double dip" by receiving both premium tax credits and cost-sharing reduction payments.

That detail matters because by late October 2017, plans, regulators, and purchasers were already working through the consequences of CSR uncertainty for the 2018 market. The Alexander-Murray bipartisan package had been framed as a market-stabilizing measure. The Hatch-Brady version would keep the CSR funding piece but attach policy changes that go well beyond insurer reimbursement.

Worth knowing. The proposal would not just change policy going forward; it would retroactively suspend the employer mandate for years that had already passed.

Health Affairs presented this as an update to the ongoing ACA round-up, and the practical question is straightforward: does Congress move a narrow insurer-stabilization bill, or does CSR funding become the vehicle for reopening fights over mandates, HSAs, and abortion policy?

How this lands in practice

If you run a practice, the immediate issue is still insurer participation and patient affordability for 2018 and 2019. CSR payments help reduce out-of-pocket costs for eligible marketplace enrollees. So the funding stream affects whether plans can price products with some confidence and whether patients face another round of churn.

A clean CSR appropriation through 2019 could, in theory, give insurers a more predictable runway. The Hatch-Brady proposal complicates that by tying the money to other ACA changes that are politically harder to pass. That raises the risk that the stabilization piece gets caught in a larger ideological negotiation.

For front-line clinicians, this usually shows up in ordinary ways. A patient asks whether her marketplace plan will still be accepted in January. A specialist's office wonders if a carrier is leaving the county. A practice manager tries to estimate bad debt because deductibles and cost sharing may change again. Policy design in Washington becomes operational friction in the exam room.

There is also a split in who feels these provisions first. Suspending the individual mandate penalty affects coverage incentives for patients in the individual market. Retroactively suspending the employer mandate is more remote from bedside care, but it still touches employer-sponsored coverage policy and could influence how benefits decisions are understood by workers and employers.

The HSA provision points in a different direction. Expanding the maximum contribution limit would favor consumers who use these accounts, typically in conjunction with high-deductible coverage. That may matter for some commercially insured patients, though it does little to answer the narrower question that insurers had been asking in 2017: will the federal government reliably make CSR payments?

The asterisks here

The Health Affairs item is an update, not a full legislative text, and that limits how much can be said about implementation. It does not spell out the mechanics of the proposed anti-double-dipping conditions for insurers, the exact abortion restrictions, or how the HSA expansion would be structured.

It also does not say whether these changes had support broad enough to move through both chambers. That is the core uncertainty. Alexander-Murray drew attention because it was bipartisan and comparatively narrow. Hatch-Brady suggests a different legislative theory: use the must-have insurer payment issue to secure conservative policy changes that had not been part of the original stabilization deal.

For physicians, the unanswered question is not academic. If the added provisions sink the package, then the underlying coverage instability remains. If some version passes, the details will determine whether the result mainly steadies the market, mainly weakens the mandates, or both.

What to watch next

The next thing to watch is whether Congress treats CSR funding as a stand-alone market fix or as leverage for a broader ACA rewrite. That distinction will determine how quickly insurers get clarity for 2018 and whether patients see any relief from plan uncertainty heading into 2019.

Watch, too, for the insurer payment language. Hatch and Brady specifically flagged concern about plans receiving both premium tax credits and CSR payments in 2018. If lawmakers pursue that condition, insurers and state regulators would need to sort through how those rules interact with pricing already underway.

For physicians and medical groups, the practical posture is cautious realism. Keep an eye on local insurer participation, marketplace patient questions, and front-desk messaging around out-of-pocket costs. In late 2017, the policy story was not just whether CSR funding would return. It was what Congress would demand in exchange.